Seoul, South Korea – Award-winning Asia-Pacific specialist CRO Novotechwill attend the 2019 KoNECT conference in Seoul, South Korea this week (Booth #15).
The Novotech CRO South Korea team will attend the conference to meet with local and international biotechs and the local clinical community.
Novotech is the leading and most experienced CRO in the region with a track-record in Asia-Pacific clinical trials spanning 23 years.
KoNECT is a one-of-a-kind conference on clinical trials in Asia, and is co-hosted by Ministry of Food and Drug Safety and supported by Ministry of Health and Welfare.
Novotech CEO Dr John Moller said:
“Novotech has recently welcomed the South Korean Government’s 5-year Plan to further support and speed-up approvals for biotech clinical trials, because it will attract more of Novotech’s US biotech clients to South Korea which already has an outstanding clinical reputation.”
The Asia-Pacific is in high-demand for biotech clinical research:
“A global migration of clinical research is occurring from high-income countries to low and middle-income countries with emerging economies. Over the period 2017 to 2018, for example, the number of clinical trial sites opened by biotech companies in Asia-Pacific increased by 35% compared to 8% in the rest of the world…” (source GlobalData)
Novotech, known as the Asia-Pacific CRO, has offices and teams through the region as well as partnerships and long-term relationships with major hospitals that directly benefit clients.
Novotech’s in-country relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets.
Novotech was established in 1996, headquartered in Australia with offices in 15 locations across the Asia-Pacific region, 3 customer-facing offices in the United States and over 20 site partnerships with major health providers.